Physician profile
Jeffrey G Weiss
NPI 1366625162
$532,426.81
in general payments reported to CMS, 2019-2025
49 companies · $138K in 2025
The $138K reported for 2025 was more than what 99% of Allergy providers received nationally (typical 2025 total: $1,129).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14K · 2020: $9,971 · 2021: $37K · 2022: $72K · 2023: $117K · 2024: $144K · 2025: $138K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $339K · Food and Beverage: $21K · Travel and Lodging: $19K · Honoraria: $11K · Consulting Fee: $9,007 · Education: $211.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $339,343.00 |
| Food and Beverage | $20,781.03 |
| Travel and Lodging | $19,383.34 |
| Honoraria | $10,500.00 |
| Consulting Fee | $9,006.78 |
| Education | $210.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $290,961.27 | 2019-2025 | Tezspire, Fasenra, Airsupra |
| Glaxosmithkline, LLC. | $159,691.78 | 2020-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Takeda Pharmaceuticals U.S.A., INC. | $23,094.89 | 2021-2025 | Cuvitru, Hyqvia, Eohilia |
| Amgen INC. | $22,991.30 | 2021-2025 | Tezspire |
| Adma Biomanufacturing LLC | $13,853.68 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $12,684.04 | 2019-2025 | |
| Consortium of Independent Immunology Clinics, LLC | $1,650.00 | 2024-2025 | |
| Genzyme Corporation | $724.30 | 2021-2025 | |
| Optinose US, INC. | $716.16 | 2021-2025 | |
| Grifols USA, LLC | $621.14 | 2021-2025 | Xembify |
| Pfizer INC. | $531.36 | 2019-2025 | |
| Csl Behring | $507.16 | 2021-2025 | Haegarda, Hizentra, Andembry |
| Genentech USA, INC. | $414.95 | 2019-2025 | Xolair |
| Abbvie INC. | $413.31 | 2022-2025 | Rinvoq |
| Kaleo, INC. | $371.88 | 2021-2024 | Auvi-Q |
Show all 48 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $335.45 | 2024-2025 | Nemluvio |
| Lilly USA, LLC | $316.81 | 2024-2025 | Ebglyss |
| Leo Pharma INC. | $310.60 | 2022-2025 | Adbry, Anzupgo |
| Regeneron Healthcare Solutions, INC. | $221.85 | 2021-2025 | Dupixent |
| Shire North American Group INC | $203.81 | 2019 | |
| Biocryst US Sales Co., LLC | $179.78 | 2022-2025 | Orladeyo |
| Covis Pharma Gmbh | $152.38 | 2021-2023 | |
| Pharming Healthcare, INC. | $143.41 | 2022-2025 | Ruconest |
| Incyte Corporation | $123.21 | 2021-2025 | Opzelura |
| Blueprint Medicines Corporation | $109.80 | 2023-2025 | Ayvakit |
| Organon LLC | $103.32 | 2025 | Vtama |
| Sanofi-Aventis U.S. LLC | $98.99 | 2024 | |
| Invivyd INC | $85.68 | 2025 | Pemgarda |
| Circassia INC. | $82.82 | 2019-2021 | |
| Aerin Medical INC. | $82.12 | 2022-2025 | |
| Teva Pharmaceuticals USA, INC. | $70.85 | 2020-2023 | Cinqair |
| Horizon Therapeutics Plc | $67.13 | 2019-2023 | Actimmune |
| Aimmune Therapeutics, INC. | $61.26 | 2021-2022 | |
| Alk-Abello, INC | $58.77 | 2022-2023 | Odactra, Ragwitek, Grastek |
| Greer Laboratories, INC. | $51.54 | 2024-2025 | Oralair |
| Cycle Pharmaceuticals INC | $44.68 | 2025 | Sajazir |
| Octapharma USA, INC. | $34.66 | 2021-2024 | Panzyga |
| Azurity Pharmaceuticals, INC. | $33.25 | 2025 | Alvesco |
| Ionis Pharmaceuticals, INC. | $33.19 | 2025 | Dawnzera |
| Hikma Pharmaceuticals USA | $30.59 | 2023 | Ryaltris |
| Merck Sharp & Dohme LLC | $29.64 | 2021-2023 | |
| Phadia US INC. | $28.81 | 2022-2023 | Immunocap |
| Gc Biopharma USA, INC. | $28.79 | 2025 | Alyglo |
| Aytu Biopharma, INC. | $16.93 | 2024 | Karbinal |
| Tersera Therapeutics LLC | $16.19 | 2022 | |
| Eyevance Pharmaceuticals LLC | $14.78 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.72 | 2022 | |
| Ars Pharmaceuticals Operations, INC. | $13.78 | 2025 | Neffy |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$5,021.52 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Weiss listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.